

and pharmaceutically acceptable salts thereof

wherein

n is 1 or 2;

A is hydrogen, C₁₋₆ alkyl, aryl, -SO₂R¹, -PO(OC₁₋₆ alkyl)₂, -PO(C₁₋₆ alkyl)₂, -CO(C₁₋₆ alkyl), -CO₂R², -(CH₂)_mCO₂H or -(CH₂)_mCO₂(C₁₋₆ alkyl),

wherein

R¹ is hydrogen, C₁₋₆ alkyl, C₃₋₇ cycloalkyl, aryl, -(CH₂)_maryl or -NR³R⁴

R² is C₁₋₆ alkyl, C₃₋₇ cycloalkyl, aryl, -(CH₂)_maryl or alkenyl, and

m is 1, 2 or 3,

wherein

aryl is unsubstituted, substituted phenyl or 5-6 membered aromatic heterocyclic ring, and

R³ and R⁴ are independently hydrogen, C₁₋₆ alkyl or C₃₋₇ cycloalkyl;

B is hydrogen;

C and D are both

phenyl unsubstituted or substituted with one or two

substituents selected from C₁₋₄ alkyl, C₁₋₄ alkoxy,

methylenedioxy, halogen, hydroxy and NR⁴R⁵, or

C₃₋₇ cycloalkyl;

E, F, and H are independently CR⁵ or N and G is N,

wherein

R^5 is hydrogen, C_{1-4} alkyl, C_{1-4} alkoxy, CF_3 , halogen, hydroxy or

$-NR^3R^4$; and

as amended I is $-C(NH)NH_2$, $-C(NH_2)NOH$, or $-CH_2NH_2$.
